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Abstract
Background: The success rate of IVF treatment is low. A recent systematic review and meta-
analysis found that the outcome of IVF treatment could be improved in patients who have
experienced recurrent implantation failure if an outpatient hysteroscopy (OH) is performed before
starting the new treatment cycle. However, the trials were of variable quality, leading to a call for
a large and high-quality randomised trial. This protocol describes a multi-centre randomised
controlled trial to test the hypothesis that performing an OH prior to starting an IVF cycle
improves the live birth rate of the subsequent IVF cycle in women who have experienced two to
four failed IVF cycles.
Methods and design: Eligible and consenting women will be randomised to either OH or no OH
using an internet based trial management programme that ensures allocation concealment and
employs minimisation for important stratification variables including age, body mass index, basal
follicle stimulating hormone level and number of previous failed IVF cycles. The primary outcome
is live birth rate per IVF cycle started. Other outcomes include implantation, clinical pregnancy and
miscarriage rates.
The sample size for this study has been estimated as 758 participants with 379 participants in each
arm. Interim analysis will be conducted by an independent Data Monitoring Committee (DMC), and
final analysis will be by intention to treat. A favourable ethical opinion has been obtained (REC
reference: 09/H0804/32).
Trail Registration: The trial has been assigned the following ISRCTN number: ISRCTN35859078
Background
Only a third of in vitro fertilization (IVF) cycles started
end in a pregnancy and one fourth result in a live birth
[1,2]. Recurrent IVF implantation failure (two or more
failed IVF cycles) is a very distressing experience to
patients [3] and increases the financial burden on the cou-
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ple or service provider. The aetiology of recurrent IVF
implantation failure can be broadly attributed to embry-
onic or uterine factors, but remains unexplained in most
cases [4]. A number of interventions have been proposed
to improve IVF outcome in such women, but many of
these interventions are not evidence-based [5,6]. As a
result, there is considerable variation in the approach to
investigations and management of recurrent IVF failure
[7].
One of the common investigations proposed after recur-
rent IVF failure is outpatient hysteroscopy (OH). OH is a
well-tolerated minimally-invasive procedure, which
allows reliable visual assessment of the cervical canal and
uterine cavity and provides the opportunity to perform
therapy in the same setting [5,8-11]. Intra-uterine pathol-
ogies have been shown to be present in 25% of infertile
patients [11]. Thus, routine OH prior to IVF has been sug-
gested by a number of investigators to ensure normality of
the uterine cavity before embryo transfer [12-19]
although this proposition has not been tested in a ran-
domised setting.
In order to capture all existing evidence on whether OH
could improve the outcome of the subsequent IVF cycle in
patients who have experienced recurrent IVF implantation
failure, we conducted a systematic review and meta-anal-
ysis [20]. We identified two randomized studies [21,22]
which examined the impact of OH on the outcome of the
subsequent IVF cycle after two or more failed IVF
attempts. Both studies included patients with normal
uterine cavity on hysterosalpingography. The researchers
in both studies performed the hysteroscopy as an outpa-
tient procedure, used a 5-mm hysteroscope with a 30°
view, reported no complications and discharged patients
within one hour after the procedure. Both studies showed
a statistically significant improvement in the clinical preg-
nancy rate in the group who had OH (pooled RR = 1.57,
95%CI 1.29-1.92, p < 0.00001). The number needed to
treat with OH in order to achieve an additional clinical
pregnancy in the study populations was 7 (95%CI 5-12).
The miscarriage rate was not statistically different between
the OH and control groups [20].
However, there were deficiencies in the quality of these 2
randomised studies. For example, one study [22] did not
report adequate concealment of allocation. Lack of con-
cealment can exaggerate effect size by up to 41% [23]. In
addition, only one of the studies [22] reported live birth
rate per IVF cycle started. Furthermore, both studies were
single-centre randomised studies, leading to limited gen-
eralisability of their findings. A well designed, adequately
powered, allocation concealed multi-centre trial is there-
fore needed to address this research question.
Methods and design
Objective
In the proposed trial we will evaluate whether performing
an OH prior to starting an IVF cycle improves the likeli-
hood of achieving a live birth after the IVF cycle in women
who have experienced two to four IVF implantation fail-
ures.
Design
A prospective, allocation concealed, single blind, multi-
centre randomised trial with health economic evaluation.
Outcomes
The primary outcome is live birth rate (beyond 24 weeks
gestation) per IVF cycle started. The secondary outcomes
are embryo implantation rate, pregnancy rate per IVF cycle
started, clinical pregnancy rate per IVF cycle started and
miscarriage rate per pregnancy achieved
Inclusion criteria
Women undergoing an IVF (with or without intracyto-
plasmic sperm injection) treatment cycle who have had
between two to four fresh IVF cycles ending in an embryo
transfer but no implantation are eligible to participate in
the trial. For the purpose of this study, implantation is
defined as the presence of an intra-uterine gestational sac
showing fetal cardiac pulsations 4 - 5 weeks after embryo
transfer.
Exclusion criteria
Women who had less than two or more than four failed
fresh IVF cycles ending in an embryo transfer, women
aged 37 years or more at the time of randomisation,
women who have had a hysteroscopy within 2 months of
randomisation, the presence of submucous or intramural
uterine fibroids distorting the uterine cavity or untreated
tubal hydrosalpinges and a body mass index (BMI) above
35 (36 or higher).
The rationale for not including women aged 37 years and
older is that the primary factor in IVF failure in this age
group is related to embryo quality, which is unlikely to be
corrected by uterine or endometrial manipulation. Sub-
mucous and intramural uterine fibroids distorting the
uterine cavity and untreated tubal hydrosalpinges are
known causes of IVF cycle failure and require specific
treatment aimed at reversing their detrimental effects.
Patients with a history of fibroids removal or treatment of
tubal hydrosalpinges will not be excluded.
Randomisation
Third party, distant, internet-based randomisation will be
used to ensure randomisation and allocation conceal-
ment. Participants will be randomised online via a secure
internet facility in a 1:1 ratio through a third party inde-Reproductive Health 2009, 6:20 http://www.reproductive-health-journal.com/content/6/1/20
Page 3 of 7
(page number not for citation purposes)
pendent Integrated Trial Management System (MedSciNet
Clinical Trial Framework) that has been designed, devel-
oped and delivered according to ISI9001-2000 standards
and compliant with FDA CFR21:11 requirements. A "min-
imisation" procedure using a computer-based algorithm
will be used to avoid chance imbalances in important
stratification variables, such as age, BMI, number of previ-
ous failed IVF cycles and basal FSH level (as dichotomous
variables). The randomised allocation will not be given
until all eligibility and stratification data have been given.
Blinding
The trial will be single-blinded, where the embryologists
involved in the embryo transfer procedure are blinded to
group allocation, thus minimising performance bias.
Measurement bias in unlikely to interfere with the trial
analysis and result due to the objective nature of the pri-
mary outcome (live birth).
Methods
The flow chart in figure 1 describes the participant flow
through the trial. Women with a history of two to four IVF
implantation failures, who fulfil the inclusion and exclu-
sion criteria, are offered information about the Trophy
trial, and invited to participate.
If the woman agrees to participate in the trial, further
information and instructions relating to the trial are given
[see Additional file 1], and she is requested to sign the trial
consent form [see Additional file 2] by a clinician. Contact
and baseline data are collected in the electronic Integrated
Trial Management System (ITMS) [see Additional file 3].
Each woman will be randomised to either the interven-
tion or the control group.
All women are given instructions to notify the clinic nurse
by telephone at the start of their menstrual cycle to inform
her of their intention to start treatment in that cycle. When
the nurse receives the call from the woman, the nurse will
randomise the patient, and if the woman is allocated to
the OH group, will book an OH within 14 days of the
beginning of menstruation. Women randomised to OH
arm will attend the respective Unit for OH within 14 days
of the beginning of menstruation. They will then be
expected to start the IVF process according to a standard
controlled ovarian stimulation protocol [24]. Women
randomised to the control group will start the IVF process
according to a standard controlled ovarian stimulation
protocol without OH.
Trial intervention
Outpatient hysteroscopy (OH)
The OH procedure will be performed in the first two
weeks of the menstrual cycle by named surgeons in each
of the participating centres (Box 1):
Box 1: Hysteroscopy Equipment
Hysteroscope
▪ Rigid hysteroscope (continuous flow; 30° forward-
oblique view) assembled in an examination sheath with
an atraumatic tip giving a total instrument outer diameter
Participants flow in the study Figure 1
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of up to 3.2 mm (often called "micro-hysteroscopy") [25].
The telescope can be used in a single- or double-flow
mode with an operative channel for 5 French instruments
for minor operative procedures, thus increasing the total
instrument diameter up to 5.0 mm. The operative 5
French instruments are either mechanical (such as croco-
dile forceps, biopsy forceps and sharp and blunt scissors)
or electrical (such as bipolar needle or coagulation probe)
Distension media
▪ An isotonic solution (0.9% Normal saline or Ringer lac-
tate) administrated via a pressure-controlled pump or
simple pressure cuff system is used. The pressure is preset
at between 80-120 mmHg with the aim to use the lowest
pressure required to distend the uterine cavity adequately.
Pre-medication
▪ No routine pre-operative analgesics, antibiotics, seda-
tives or cervical preparation is used. A pelvic ultrasound
scan should be performed before the procedure is started.
All women must have a negative pregnancy test prior to
commencing the procedure.
Procedure
▪ Before the hysteroscopy is performed, the woman is fully
counselled by the clinician and requested to sign a con-
sent form.
▪ The woman is positioned in the dorso-lithotomy (semi-
recumbent) position using comfortable leg rests.
▪ The perineum should be at the edge of the couch with
the coccyx and sacrum well supported by the table.
▪ Either the 'touch' (Cuscoe's speculum) or 'no touch'
(vaginoscopy) techniques is acceptable.
 Antiseptic preparation of the ectocervix is at the dis-
cretion of the operator (e.g. chlorhexidine)
▪ Entry into the uterine cavity is under direct vision using
gentle manipulation to minimise trauma to the cervical
canal.
 The use of minimal cervical dilatation is to be
restricted to cases of cervical stenosis. A tenaculum can
be applied to the anterior lip of the cervix to help
straighten the cervical canal.
▪ Local cervical anaesthesia (direct cervical or para-
cervical infiltration) using short acting local anaes-
thetic (lidocaine or mepivicaine) may be adminis-
tered at the discretion of the operator to facilitate a
minor degree of cervical dilatation and after
obtaining the woman's consent.
▪ On entering the uterine cavity a systematic inspection
should be conducted to include
 Panoramic inspection of the uterine cavity at the
level of the uterine isthmus
 Inspection under higher magnification of the uterine
cornua, tubal ostia, uterine fundus, lateral walls, ante-
rior and posterior uterine walls.
 Information to be recorded must include (See Addi-
tional file 3):
▪ The appearance of the endometrium.
▪ Shape of the uterine cavity [regular vs. irregular
contour; normal vs. enlarged vs. tubular
(restricted) size]
▪ Presence and location of structural anomalies
(polyps, fibroids, adhesions, congenital anoma-
lies)
▪ The entire intra-cervical canal should be inspected whilst
slowly withdrawing the hysteroscope.
▪ Uterine dimensions estimated and recorded to include
 Cervical canal length (cm)
▪ Cervical canal length should be obtained by visu-
alising the internal cervical os, with the distal tip of
the hysteroscope at this level and the operator's
finger pressed against the shaft of the telescope to
mark the level of the external cervical os.
 Uterine sound length (cm)
 Uterine cavity length [uterine sound length - cervical
canal length (cm)]
 If uterine polyps, small submucous fibroids (≤ 0.5
cm diameter) or filmy adhesions are identified, simul-
taneous mechanical hysteroscopic treatment should
be attempted and the feasibility and outcome of such
procedures recorded.
Post-procedure
▪ Patients should be observed for a minimum period of 30
minutes in a sitting recovery area before being allowed toReproductive Health 2009, 6:20 http://www.reproductive-health-journal.com/content/6/1/20
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leave the clinic. Simple analgesics (e.g. paracetamol or
diclofenac) may be administered if required.
Clear and accurate surgical data will be routinely collected
on each patient recruited via a specific 'hysteroscopy find-
ings chart' [see Additional file 3]. These data will be ana-
lysed for specific findings, and for rates of adverse events
or treatment failures.
The first outcome assessment (pregnancy test) will be
done approximately two weeks after egg collection. The
second and third outcome assessments (clinical preg-
nancy and implantation) will be done via ultrasound scan
performed between 6-7 weeks of gestation at the respec-
tive trial centres.
The primary outcome assessment (live birth beyond 24
weeks) is conducted after delivery to gather data on deliv-
ery outcomes. A member of the local research team will
also check birth registers and in-patient records to track
hospital admissions and pregnancy outcomes.
Trial statistics
Number of participants
Sample size calculation was based on the observed IVF
cycle outcome and differences in outcome from existing
literature as well as on the judgement on what constitutes
as a clinically Minimally Important Difference (MID). The
MID was judged to be increasing the live birth rate per
cycle started by 10% (from 25% to 35%). For this differ-
ence of 10% increase in the live birth rate, and for a power
of over 80% and a double sided alpha error of 5%, 720
women in total will need to be recruited (360 in each arm
of the trial). In order to allow for a "worst case scenario"
dropout rate of 5%, we intend to recruit 758 women in
total (379 in each arm of the trial). The base rate of 25%
was based conservatively on the control arms of the stud-
ies included in the published systematic review [20] and
the MID of 10% was defined following consultations with
fertility practitioners. This difference is much smaller than
has been suggested by existing literature [22], which has
reported an overall 75% relative improvement in IVF cycle
outcome. Hence, assuming a conservative actual absolute
difference of 15% (25% to 40%) in live birth rate beyond
24 weeks, 758 participants will provide a power of 96% at
a double sided alpha error of 1%. Based on a comprehen-
sive audit data covering over 4,000 IVF cycles, approxi-
mately 40% of patients seen in participating centres will
be eligible for inclusion in the study. Assuming a modest
50% recruitment rate, the target of 758 patients could be
randomised in 24 months. This recruitment rate is realis-
tic and easily achievable given that there are no similar tri-
als ongoing in participating centres, and IVF patients are
generally motivated to participate in research [26].
Statistical analysis
The analysis will be by intention to treat, and will be car-
ried out in the following four steps:
Step 1: Summarising trial data
Baseline and outcome data will be summarised sepa-
rately. For continuous variables, we will examine the dis-
tribution of the observations, and if normally distributed
we will summarise them as means with standard devia-
tions (SD). If they are non-normally distributed, then
medians and inter-quartile ranges (IRQs) will be reported.
Appropriate transformation will also be considered. For
dichotomous data (e.g. pregnancy, implantation, clinical
pregnancy and live birth), we will provide proportions (or
percentages). In addition to baseline and outcome data,
we will also summarise the recruitment numbers, those
participants lost to follow-up, protocol violations and
other relevant data. We will prepare a CONSORT flow dia-
gram to display these results.
Step 2: Inter-group comparisons
The statistical procedures for comparisons will depend on
the nature of the data: for example, for dichotomous out-
comes, we will use Fisher's Exact Test or Chi-square as
appropriate, and for continuous outcomes we will use t-
test if the observations in each trial arm are normally dis-
tributed; if non-normally distributed, then Mann-Whit-
ney-U test will be employed.
We appreciate that multitudes of comparisons can suffer
from Type I (false-positive) error, and will therefore deter-
mine the success or failure of the study in terms of the sin-
gle primary endpoint on which the power calculations are
based: the live birth rate. Although p-values will be
reported, the focus will be on providing 95% confidence
intervals around point estimates as these are more useful
in interpreting the findings of the trial.
Step 3: Sub-group analysis
We will give emphasis to analysis within planned (a pri-
ori) sub-groups (namely normal versus abnormal hyster-
oscopic findings). However, we are aware sub-group
analysis is limited by statistical power and can suffer from
false positive (due to multiplicity of comparisons) and
false negative (due to reduced sample sizes) results, and
will place limited importance on sub-group analysis find-
ings in relation to the overall (global) findings. We will
use post-hoc sub-group analysis only for the purpose of
hypothesis generation.
Step 4: Adjustments and sensitivity analyses
If randomisation fails to achieve balanced groups, then we
will perform secondary analyses in which we will adjust
for unbalanced prognostic factors using procedures such
as logistic regression. If the primary unadjusted analysisReproductive Health 2009, 6:20 http://www.reproductive-health-journal.com/content/6/1/20
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and secondary adjusted analysis are at discordance, then
we will give greater weighting to the primary analysis in
the interpretation of trial findings. For issues such as
losses to follow-up, missing data and protocol violations,
we will attempt sensitivity analyses to explore the effect of
these factors on the trial findings. As a secondary analysis,
we will adjust for missing data using imputation tech-
niques to explore the effects of such imputations on the
trial findings.
Interim Analysis and Data and Safety Monitoring
The trial will commission an independent Data Monitor-
ing Committee (DMC). The DMC will have independent
members with clinical and statistical background, who
have no conflict of interest relating to the two trial arms
and have no involvement in running any part of the trial.
The DMC will be responsible for Data and Safety Monitor-
ing.
During the trial, the DMC will perform interim analysis
and review unblinded outcome data for safety and effi-
cacy, initially after primary outcome data are available for
35% of the trial participants, and subsequently at six
monthly intervals.
The DMC will review unblinded outcome data for safety
and efficacy following interim analyses at intervals stated
above applying the following Statistical Warning Rule,
which is: (i) Doubling of the clinical pregnancy rate in
one of the two groups compared to the other, with a sta-
tistical significance of P ≤ 0.001 on two consecutive
interim analysis, (ii) Overwhelming evidence regarding
the relative safety of the two trial arms, sufficient to make
continuing randomisation unethical. The DMC will
advice the Trial Steering Committee of any clear evidence
that one approach is preferable or if there is an unaccept-
able level of serious adverse events.
Withdrawal of Subjects
There will be no replacement of trial subjects who have
withdrawn from the study, and as the analysis is by Inten-
tion-To-Treat (ITT), if outcome data are available for with-
drawn study participants, they will be analysed according
to the group to which they were randomised.
Ethics and Confidentiality
This trial will be conducted according to the Principles of
Good Clinical Practice as defined in the Medicines for
Human Use (Clinical Trials) Amended Regulations 2006,
the Research Governance Framework for Health & Social
Care 2005 and the Data Protection Act. The trial has
already received a favourable ethical opinion from a
Regional Ethics Committee (REC).
Patient notes containing their personal and treatment
details will be kept within the respective Units according
to the statutory requirements of the HFE Act 1990 and the
strict confidentiality that it requires. Notes from patients
who have achieved a pregnancy will be kept or archived
for 50 years. Patients will need to give their written con-
sent before any of their treatment details or personal
information is passed to their General Practitioners or any
other persons who are not covered by an HFEA licence.
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